<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429273</url>
  </required_header>
  <id_info>
    <org_study_id>P50MH077248-01</org_study_id>
    <secondary_id>P50MH077248-01</secondary_id>
    <secondary_id>DDTR B2-NDH</secondary_id>
    <secondary_id>10-000453</secondary_id>
    <nct_id>NCT00429273</nct_id>
  </id_info>
  <brief_title>Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder</brief_title>
  <acronym>Project1</acronym>
  <official_title>An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of a single drug versus a combination of drugs in
      treating attention deficit hyperactivity disorder in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood mental
      disorders. Children with ADHD have impaired functioning in multiple settings, including home
      and school. They also have difficulty relating with peers. If left untreated, the disorder
      may cause adverse effects that can last into adolescence and adulthood. Stimulant
      medications, such as methylphenidate, are effective in reducing ADHD symptoms on a short-term
      basis. However, few long-term benefits in academic or general functioning from current ADHD
      therapies have been demonstrated. Focalin XR is a stimulant medication that is FDA-approved
      for treating ADHD. Guanfacine is another medication that is currently approved for the
      treatment of hypertension, but has long been used for treating ADHD. This study will
      determine the effectiveness of a combination of Focalin XR and guanfacine in enhancing
      cognitive functioning and improving the long-term benefit of ADHD treatment.

      Participants in this study will be randomly assigned to one of three treatment regimens:
      Methylphenidate (Focalin XR) and placebo; guanfacine and placebo; or Focalin XR and
      guanfacine. The study will be conducted in two phases: an 8-week double-blind treatment phase
      and a 12-month open-label treatment phase. In Phase I, one third of participants will receive
      placebo for the initial 4 weeks, followed by Focalin XR alone for the remaining 4 weeks. All
      other participants will receive their assigned medications for the full 8 weeks. All
      participants will attend two study visits prior to beginning treatment and one study visit
      per week throughout Phase I. At the end of Phase I, treatment assignments will be unblinded.
      Participants who experienced adequate improvement with their assigned treatment will then
      continue in Phase II on the same medication(s) for an additional 12 months. Participants will
      attend study visits once per month until the end of the study. Study visits will include
      self-report measures, clinical assessments, and cognitive testing. Participants will also
      undergo four electroencephalography (EEG) tests and two fMRI scans over the course of the
      study. All Phase II participants will receive a follow-up telephone call 1 month after the
      final study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)</measure>
    <time_frame>Measured at baseline Week 4 and Week 8</time_frame>
    <description>The primary clinical efficacy variable for treatment was the ADHD-RS-IV Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).
The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3).
Scores are obtained by summing each item; The higher the score, the worse the outcome.
Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Group 1: Guan-Guan+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo-Placebo+DMPH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weeks 1-4: Placebo weeks 5-8: Placebo+DMPH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Guan-Guan+DMPH (Comb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures</description>
    <arm_group_label>Group 1: Guan-Guan+Placebo</arm_group_label>
    <arm_group_label>Group 3: Guan-Guan+DMPH (Comb)</arm_group_label>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate (MPH)</intervention_name>
    <description>Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.</description>
    <arm_group_label>Group 2: Placebo-Placebo+DMPH</arm_group_label>
    <arm_group_label>Group 3: Guan-Guan+DMPH (Comb)</arm_group_label>
    <other_name>Focalin XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of DSM-IV ADHD by K-SADS-PL and confirmed by clinical interview

          -  Clinical Global Impression-Severity score of at least 4 for ADHD

          -  Resided with primary caretaker for at least 6 months prior to study entry

        Exclusion Criteria:

          -  History of autism, pervasive developmental disorder, chronic tic disorder, psychosis,
             or bipolar disorder

          -  Current major depression or panic disorder

          -  Systolic or diastolic blood pressure at screening greater than the 95th percentile or
             less than the 5th percentile for age and body mass index (BMI)

          -  Any medical condition that might make stimulant or alpha agonist therapy medically
             inadvisable

          -  Need for chronic use of other medications with central nervous system effects

          -  Pregnant, breastfeeding, or beyond menarche and has a positive urine pregnancy test

          -  History of structural heart defects, syncope, or fainting while exercising

          -  Clinically significant cardiac abnormality as determined by echocardiogram (ECG) at
             study entry

          -  Mental retardation as determined by clinical functional assessment and an IQ estimate
             of less than 70 based on Wechsler Adult Intelligence Scale (WAIS) subtests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James T. McCracken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James J. McGough, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>James McCracken</investigator_full_name>
    <investigator_title>Chair</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Guanfacine</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Focalin XR</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>212 randomized (deemed eligible and enrolled). 71 randomized to Group 1: 3 dropped prior to receiving drug; thus 68 started drug.
70 randomized to Group 2: 1 dropped before receiving drug; thus 69 started drug.
71 randomized to Group 3:1 dropped before receiving drug; thus 70 started drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Guan-Guan+Placebo</title>
          <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine+Placebo</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Placebo-Placebo+DMPH</title>
          <description>weeks 1-4: Placebo weeks 5-8: Placebo+DMPH</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Guan-Guan+DMPH</title>
          <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH (comb)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Guan-Guan+Placebo</title>
          <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine +Placebo</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Placebo-Placebo+DMPH</title>
          <description>weeks 1-4: Placebo weeks 5-8: Placebo+DMPH</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Guan-Guan+DMPH (Comb)</title>
          <description>weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH (comb)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" spread="2.1"/>
                    <measurement group_id="B2" value="10.1" spread="2.0"/>
                    <measurement group_id="B3" value="9.9" spread="2.2"/>
                    <measurement group_id="B4" value="10.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>of the 212 participants randomized, 207 received at least one dose of study drug and form the safety and intent-to-treat samples.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)</title>
        <description>The primary clinical efficacy variable for treatment was the ADHD-RS-IV Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).
The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3).
Scores are obtained by summing each item; The higher the score, the worse the outcome.
Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27</description>
        <time_frame>Measured at baseline Week 4 and Week 8</time_frame>
        <population>Every contrast includes estimates of maturation/time trend and the within subject covariance structure based on all participants using full information maximum likelihood estimation.</population>
        <group_list>
          <group group_id="O1">
            <title>Estimated Difference Between Guan and Placebo</title>
            <description>Contrasts based on all observations of patients treated with guam and all patients on placebo controlling for time effects. For placebo this included patients in the guan-guan arm at baseline, the guan-combo arm at baseline, and the placebo-DMPH arm at baseline and 4 weeks, while the estimates for guan are based on the guan-guan arm both at 4 weeks and 8 weeks, and the guan-combo arm at 4 weeks only. Participant specific effects and time effects are controlled for based on estimates from all participants and all time points.</description>
          </group>
          <group group_id="O2">
            <title>Estimated Difference Between DMPH and Placebo</title>
            <description>Contrasts based on all observations of patients treated with dmph and all patients on placebo controlling for time effects. For placebo this included patients in the guan-guan arm at baseline, the guan-combo arm at baseline, and the placebo-DMPH arm at baseline and 4 weeks, while the estimates for DMPH are based on the placebo-guan arm at 8 weeks. Participant specific effects and time effects are controlled for based on estimates from all participants and all time points.</description>
          </group>
          <group group_id="O3">
            <title>Estimated Difference Between Placebo and Combo</title>
            <description>Contrasts based on all observations of patients treated with combo and all patients on placebo controlling for time effects. For placebo this included patients in the guan-guan arm at baseline, the guan-combo arm at baseline, and the placebo-DMPH arm at baseline and 4 weeks, while the estimates for DMPH are based on the guan-combo arm at 8 weeks. Participant specific effects and time effects are controlled for based on estimates from all participants and all time points.</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)</title>
          <description>The primary clinical efficacy variable for treatment was the ADHD-RS-IV Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).
The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3).
Scores are obtained by summing each item; The higher the score, the worse the outcome.
Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27</description>
          <population>Every contrast includes estimates of maturation/time trend and the within subject covariance structure based on all participants using full information maximum likelihood estimation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total ADHD-RS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.77" spread="1.70"/>
                    <measurement group_id="O2" value="-7.99" spread="1.22"/>
                    <measurement group_id="O3" value="-10.66" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inattentive Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.14" spread="0.99"/>
                    <measurement group_id="O2" value="-4.10" spread="0.71"/>
                    <measurement group_id="O3" value="-5.89" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactive Impulsive Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.73" spread="0.92"/>
                    <measurement group_id="O2" value="-4.0" spread="0.69"/>
                    <measurement group_id="O3" value="-5.10" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses are based on a generalized linear mixed model (GLMM) modelling the effects of the medication when calibrated to optimal dosage and controlling for time effects and within-subject effects. The design is a combined within-between subject design, where each participant is exposed to, and provides information about multiple tx modalities.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for differences in treatment outcomes between three different tx</non_inferiority_desc>
            <p_value>&lt;.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>F-Value for variance component</param_type>
            <param_value>18.90</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Guan-Guan+Placebo</title>
          <description>week 1-4: Guanfacine weeks 5-8: Guanfacine+Placebo</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Placebo-Placebo+DMPH</title>
          <description>week 1-4: Placebo week 5-8: Placebo+DMPH</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Guan-Guan+DMPH</title>
          <description>week 1-4: Guanfacine week 5-8: Guanfacine+DMPH (comb)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="68"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="68"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="68"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="68"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="68"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="69"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="68"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="69"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="68"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Affect Lability</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Larger group sizes would enable more conclusive tests of treatment differences; Study design began with guanfacine first and addition of a stimulant second, making difficult to compare to those study designs adding guanfacine to ongoing stimulants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James T. McCracken, M.D.</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310-825-0470</phone>
      <email>jmccracken@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

